IDEAYA Biosciences (IDYA) said Tuesday an independent data monitoring committee has recommended a move-forward dose for a potential registration-enabling phase 2/3 trial to evaluate the company's darovasertib combined with Pfizer's (PFE) crizotinib in patients with a certain metastatic uveal melanoma.
Chief Medical Officer Darrin Beaupre said the committee's recommendation allows the company to complete the part 2a of the trial and continue to enroll in part 2b.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments